Health & Safety
New Hydrodissection Treatment Offers Long-Term Relief for Carpal Tunnel Syndrome
A recent clinical trial published in October 2026 suggests a 15-minute, steroid-free ultrasound-guided hydrodissection treatment provides lasting relief for carpal tunnel syndrome, potentially preventing surgery.
Share this article
THE PRIMARY BRIEF
- 01 · The primary finding
A clinical trial published in October 2026 found that a 15-minute, steroid-free ultrasound-guided hydrodissection treatment provides long-lasting relief for carpal tunnel syndrome, with 85.7% of treated wrists showing sustained improvement at 24 weeks.
- 02 · The primary evidence
The study, published in *Radiology*, involved 63 wrists from 39 adult patients with carpal tunnel syndrome, demonstrating that hydrodissection groups maintained clinical and morphological improvements at 12 and 24 weeks, unlike the corticosteroid-only group.
- 03 · Why it matters
This minimally invasive treatment offers a durable alternative to traditional steroid injections, which provide temporary relief and carry side effects, potentially helping patients avoid surgery for a common condition affecting 5% to 10% of the population.
A new clinical trial published in Radiology in October 2026 indicates that a 15-minute, steroid-free ultrasound-guided hydrodissection treatment offers long-lasting relief for carpal tunnel syndrome, potentially helping patients avoid surgery.
This development is significant because carpal tunnel syndrome affects 5% to 10% of the general population, with rising incidence rates. Traditional steroid injections often provide only temporary relief and carry risks such as localized skin changes, fat thinning, and tendon weakening. The new minimally invasive procedure could offer a safer, more durable alternative.
What the Records Show
Participants were divided into three groups: one receiving ultrasound-guided hydrodissection with normal saline, another receiving a traditional ultrasound-guided corticosteroid injection alone, and a third receiving hydrodissection with both saline and corticosteroid. The hydrodissection procedure involves injecting sterile saline around the compressed median nerve in the wrist to free it from surrounding tissues.
All three treatment groups initially showed improvement. However, at 12 weeks and 6 months (24 weeks) post-treatment, the hydrodissection groups demonstrated sustained clinical and morphological improvements. In contrast, the corticosteroid-only group experienced a recurrence of symptoms. Specifically, at 24 weeks, 85.7% of wrists treated with saline hydrodissection and 90.5% of those treated with hydrodissection plus corticosteroid achieved a clinically meaningful improvement in symptom severity. None in the corticosteroid-only group maintained this level of improvement. Pain scores in the hydrodissection groups significantly decreased and remained low, while returning to baseline by 24 weeks in the corticosteroid-only group.
Ultrasound findings supported these clinical results. The median nerve's cross-sectional area reduced by approximately 43-45% following hydrodissection, compared to about 11% after corticosteroid injection alone. The study also found that adding corticosteroids to the hydrodissection procedure did not provide any significant extra long-term benefit. The procedure itself averaged 15 minutes and was well-tolerated by patients, with no significant immediate or delayed complications observed. Only 8% of participants reported minor pain and swelling, which resolved within 3-4 days.
What Changed and for Whom
What the Subject Has Said Publicly
What We Could Not Confirm
SHOW YOUR WORK